With rates of oral cancer linked to HPV infection on the rise, a group of investigators has pinned down a new biomarker that can be used to identify high-risk patients.
Global concern is growing over the outbreak of H7N9 avian influenza in China. So far, 133 cases of H7N9 sickness have been confirmed, and at least 37 deaths are deaths are thought to have been caused by the disease.
In 2007, Merck spent $100 million promoting its human papillomavirus vaccine, Gardasil. The advertising blitz helped sales top $1 billion, but earnings fell away quickly over the next few years. Many people are critical of the vaccine, but lots more simply do not know it exists.
GlaxoSmithKline and Merck are slashing the prices of their HPV vaccinations in a deal with the GAVI Alliance, which delivers immunizations to the developing world.
Social issues have held back uptake of GlaxoSmithKline and Merck human papillomavirus (HPV) vaccines in the U.S., but globally the problem is more fundamental--the shots cost too much. It is these low-income countries--where 85% of cervical cancer cases occur--that need the vaccines most though.
New research suggests that two doses of human papillomavirus vaccine could be as effective as the current three-dose regimen, which would increase uptake.
The company plans to spend the capital on advancing a pipeline of vaccines, including a Phase II trial for a candidate called ProCervix for patients with high-risk cases of human papillomavirus (HPV) infection.
Could Australia's success with HPV vaccination help boost similar efforts in the U.S.? If hard numbers on results could help, then yes. A BMJ study shows that immunizing young women against the human papillomavirus has already proven its worth.
Public health experts are worried about the latest numbers on HPV vaccine uptake. After all, the shots can prevent cervical cancer, and that's no small thing. so, with a majority of girls eschewing the shots, government officials and others are trying to figure out how to turn the tide.
Convincing patients of the merits of human papillomavirus (HPV) vaccines has proved a tricky task for Merck ($MRK) and GlaxoSmithKline ($GSK).